Fanapt was previously approved by the FDA in 2009 as an antipsychotic treatment for schizophrenia.
FDA Approves Vanda Pharmaceuticals' Fanapt to Treat Adults with Bipolar I Disorder
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours